Tag: Presbyopia

Presbyopia is a natural, age-related condition affecting 128 million worldwide, often addressed  with traditional solutions like reading glasses or progressive lenses. However, a groundbreaking  alternative is emerging: QLOSI™, a new presbyopia treatment featuring a 0.4% pilocarpine  hydrochloride ophthalmic solution.

LNZ100 represents a new generation of miotic eye drops, which, unlike its predecessors, is not based on pilocarpine. Instead, it uses aceclidine, a unique muscarinic agonist selective for the iris’s smooth muscle, facilitating pupil constriction with negligible influence on the ciliary muscle. This distinction is essential to achieve a smaller pinhole pupil without a myopic shift. 

The conversation delved into the science behind aceclidine, its advantages over existing treatments like pilocarpine, and its potential to revolutionize presbyopia management.

How do you get the MAXimum return on Presbyopia? Dr. Harbir Sian sits down with Drs. Danielle Richardson and Melody Tavakoli to discuss presbyopia. All three experts share their knowledge and presbyopic contact lens cases to overcome challenges fitting multifocal contact lens patients.

April 5, 2022 VUITY is the first and only eye drop to treat presbyopia, or age-related blurry near vision, in adults and is FDA-approved for...

Allergan, an AbbVie (NYSE: ABBV) company, today announced the U.S. Food and Drug Administration (FDA) approval of VUITY™ (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. VUITY is the first and only FDA-approved eye drop to treat this common and progressive eye condition that affects 128 million Americans, nearly half of the U.S. adult population.

Patient-reported outcomes presented at the meeting showed that patients who received AGN-190584 versus the vehicle (placebo) reported clinically meaningful and statistically significant greater improvement in ability and satisfaction related to near-vision reading as well as reduction in use of presbyopia coping mechanisms during the last seven days of the trial.

Millennials, Meet Presbyopia. In the conversations around building a practice, doctors often focus on niche and specialty care. But there is plenty of untapped potential to grow a thriving and busy practice around serving the needs of patients that are in your chair. Studies show that in the average optometry practice, 40% of patients are over age 40. And those numbers are poised to grow even larger; the oldest millennials turn 40 in 2021, and at 73 million people, they are the largest living generation in the USA, accounting for 25% of the total population.